Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Psyence Biomedical Ltd. - Warrant
No Price
29.04.2026 14:12
Current Prices from Psyence Biomedical Ltd. - Warrant
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
NASDAQ
PBMWW
USD
29.04.2026 14:12
0,03 USD
-0,002 USD
-8,65 %
IEX
PBMWW
USD
24.04.2026 14:34
0,04 USD
-
Company Profile for Psyence Biomedical Ltd. - Warrant Share
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
